Efficacy and safety of oral versus intravenous ascorbic acid for anaemia in haemodialysis patients

Nephrology

Volumn 10, Issue 4, 2005, Pages 336-340

  Chan, Doris ^a,b   Irish, Ashley ^a   Dogra, Gursharan ^a,c,d  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^d ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Anaemia; Ascorbic acid; Erythropoietin hyporesponsiveness; Haemodialysis; Iron overload

Indexed keywords

ASCORBIC ACID; FERRITIN; HEMOGLOBIN; IRON; OXALIC ACID; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; BIOAVAILABILITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART LEFT VENTRICLE FUNCTION; HEMODIALYSIS PATIENT; HUMAN; IRON OVERLOAD; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; NEPHROLITHIASIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; ADULT; AGED; ANEMIA; ASCORBIC ACID; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 28444446642     PISSN: 13205358     EISSN: 14401797     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2005.00424.x     Document Type: Article

References (20)

1. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. National Kidney Foundation-Dialysis Outcomes Quality Initiative. Am. J. Kidney Dis. 1997; 30 (Suppl. 3): S192-240.
2. Fishbane S, Frei GL, Maesaka J. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am. J. Kidney Dis. 1995; 26: 41-6.
3. Tarng DC, Chen TW, Huang TP. Iron metabolism indices for early prediction of the response and resistance to erythropoietin therapy in maintenance hemodialysis patients. Am. J. Nephrol. 1995; 15: 230-37.
4. Tarng DC, Huang TP, Chen TW, Yang WC. Erythropoietin hyporesponsiveness: From iron deficiency to iron overload. Kidney Int. Suppl. 1999; 69: S107-18.
5. Drueke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol. Dial. Transplant. 2001; 16 (Suppl. 7): 25-8.
6. Tarng DC, Huang TP. A parallel, comparative study of intravenous iron versus intravenous ascorbic acid for erythropoietin-hyporesponsive anaemia in haemodialysis patients with iron overload. Nephrol. Dial. Transplant. 1998; 13: 2867-72.
7. Tarng DC, Wei YH, Huang TP, Kuo BI, Yang WC. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia. Kidney Int. 1999; 55: 2477-86.
8. Gastaldello K, Vereerstraeten A, Nzame-Nze T, Vanherweghem JL, Tielemans C. Resistance to erythropoietin in iron-overloaded haemodialysis patients can be overcome by ascorbic acid administration. Nephrol. Dial. Transplant. 1995; 10 (Suppl. 6): 44-7.
9. Giancaspro V, Nuzziello M, Pallotta G, Sacchetti A, Petrarulo F. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: A clinical trial. J. Nephrol. 2000; 13: 444-9.
10. Sezer S, Ozdemir FN, Yakupoglu U, Arat Z, Turan M, Haberal M. Intravenous ascorbic acid administration for erythropoietin-hyporesponsive anemia in iron loaded hemodialysis patients. Artif. Organs 2002; 26: 366-70.
11. Lin CL, Hsu PY, Yang HY, Huang CC. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload. Ren. Fail. 2003; 25: 445-53.
12. Deira J, Diego J, Martinez R et al. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia. J. Nephrol. 2003; 16: 703-9.
13. Keven K, Kutlay S, Nergizoglu G, Erturk S. Randomized, crossover study of the effect of vitamin C on EPO response in hemodialysis patients. Am. J. Kidney Dis. 2003; 41: 1233-9.
14. Ono K. Secondary hyperoxalemia caused by vitamin C supplementation in regular hemodialysis patients. Clin. Nephrol. 1986; 26: 239-43.
15. Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Arch. Intern. Med. 1985; 145: 1217-21.
16. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am. J. Kidney Dis. 1996; 28: 53-61.
17. Albitar S, Genin R, Fen-Chong M, Serveaux MO, Bourgeon B. High dose enalapril impairs the response to erythropoietin treatment in haemodialysis patients. Nephrol. Dial. Transplant. 1998; 13: 1206-10.
18. Hayashi K, Hasegawa K, Kobayashi S. Effects of angiotensin-converting enzyme inhibitors on the treatment of anemia with erythropoietin. Kidney Int. 2001; 60: 1910-16.
19. Deicher R, Horl WH. Vitamin C in chronic kidney disease and hemodialysis patients. Kidney Blood Press. Res. 2003; 26: 100-6.
20. Horl WH. Is there a role for adjuvant therapy in patients being treated with epoetin? Nephrol. Dial. Transplant. 1999; 14 (Suppl. 2): 50-60.